HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Traditional Chinese Medicine

792.148

-25.963-3.17%

Number of Gainers:1

Number of Losers:9

Number of Flat:1

PE:- -

High:815.271

Open:815.271

Low:785.175

Close:818.112

Volume:71.07M

Turnover:309.61M

Market Cap:83.11B

Float Cap:55.93B

Loading ...

PuraPharm completes issuance of HKD 20 million convertible bonds

Tong Ren Tang Chinese Medicine's Profit Slides 21% in 2025; Shares Down 5%

MT Newswires Live

China Traditional Chinese Medicine Swings to Loss in 2025; Shares Fall 4%

MT Newswires Live

China Traditional Chinese Medicine (SEHK:570) Half Year Loss Challenges Turnaround Narrative

Simply Wall St.

TRAD CHI MED (00570) Reports Annual Net Loss of RMB 458 Million, Swinging from Prior Year's Profit

BAIYUNSHAN PH (00874) Announces Final Dividend of HK$0.45 Per Share

BAIYUNSHAN PH Reports Annual Results with 5.21% Increase in Net Profit

China Traditional Chinese Medicine Holdings - Loss for Year RMB458.1 Mln

THOMSON REUTERS

China Traditional Chinese Medicine FY2025 revenue fell 10.7% to RMB 14.74 billion, adjusted net profit dropped 47.5% to RMB 333.35 million

Tong Ren Tang Technologies subsidiary Tong Ren Tang Chinese Medicine posts 2025 profit of HKD 416.86 million

Tongrentang CM to Distribute Final Dividend of HK$0.37 Per Share on June 26

Modern Chinese Medicine Group sets board meeting to approve annual results and consider final dividend

GPC and Baiyunshan Launch Phase One of Financial Transformation Initiative

Baiyunshan Pharma's Subsidiary Gets Nod for Xu Han Ting Granules' Trial As Respiratory Treatment

MT Newswires Live

Hong Kong Market Announcements: Ant Group's Acquisition of Bright Smart Receives Approval, Trading Resumes March 17

Clinical Trial Application for Baiyunshan's Xuhanting Granules in Pediatric Recurrent Respiratory Infections Receives Approval

Baiyunshan Receives SSE Approval for Guangzhou Pharmaceutical Receivables ABS Listing

China Traditional Chinese Medicine Holdings schedules board meeting to approve 2025 final results and dividend decision

Jacobson Pharma, JBM Renew Logistics, Manufacturing Agreements

MT Newswires Live

JPMorgan Reduces Stake in BAIYUNSHAN PH, Selling 207,200 Shares at HK$18.75 Each

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1606/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","market":"HK","secType":"PLATE","nameCN":"Traditional Chinese Medicine","latestPrice":792.14844,"timestamp":1774253287512,"preClose":818.1115,"halted":0,"volume":71069609,"delay":0,"changeRate":-0.031735,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-25.963074,"latestTime":"03-23 16:00:00","open":815.27057,"high":815.27057,"low":785.17505,"amount":309607360,"amplitude":0.036787,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774229400000,1774238400000],[1774242000000,1774252800000]],"pbRate":0.889945,"peRate":14.579055,"turnoverRate":0.004561,"increases":1,"decrements":9,"flats":1,"marketCap":83110969920,"floatMarketCap":55934680960},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","high":815.27057,"amplitude":0.036787,"preClose":818.1115,"low":785.17505,"pbRate":"0.889945","latestPrice":792.14844,"volume":71069609,"delay":0,"open":815.27057,"prevYearClose":830.6915,"prevWeekClose":818.111,"prevMonthClose":873.43,"prevQuarterClose":830.692,"fiveDayClose":840.647,"twentyDayClose":903.549,"sixtyDayClose":851.447,"secType":"PLATE","market":"HK","turnoverRate":0.004561,"peRate":14.579055,"marketCap":83110969920,"floatMarketCap":55934680960,"timestamp":1774253287512,"nameCN":"Traditional Chinese Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1606\",,,,undefined,":{"bkCode":"BK1606","up":1,"down":9,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1606\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621089787","title":"PuraPharm completes issuance of HKD 20 million convertible bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2621089787","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621089787?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:52","pubTimestamp":1774266749,"startTime":"0","endTime":"0","summary":"PuraPharm completed the issuance of convertible bonds with an aggregate principal amount of HKD 20 million.Completion occurred after all conditions under the subscription agreement were fulfilled.At an initial conversion price of HKD 0.49, full conversion would result in 40,816,326 new shares.The conversion shares would represent about 7.62% of existing issued share capital and about 7.08% on a fully converted basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PuraPharm Corp. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLblQym9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01498","BK1191","BK1606"],"gpt_icon":0},{"id":"2621477875","title":"Tong Ren Tang Chinese Medicine's Profit Slides 21% in 2025; Shares Down 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621477875","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621477875?lang=en_us&edition=fundamental","pubTime":"2026-03-23 15:44","pubTimestamp":1774251870,"startTime":"0","endTime":"0","summary":"Beijing Tong Ren Tang Chinese Medicine  recorded a 21% decline in attributable profit for 2025 to HK$397.2 million from HK$500.3 million a year prior, according to a Friday Hong Kong bourse filing.Shares of the medicine manufacturer were down nearly 5% in Monday afternoon trading.Earnings per share stood at HK$0.47, down from HK$0.60 in the corresponding period of the last fiscal year.Revenue slipped 6.1% year over year to HK$1.51 billion from HK$1.61 billion driven by an 11.9% decline in revenue in the Hong Kong market and an 18.3% drop in revenue in the Chinese mainland market.The company recommended a final dividend of HK$0.37 per share and a special dividend of HK$0.03 per share for the year, payable on or before June 26 to shareholders of record on June 18, subject to shareholder approval.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","03613","BK1606"],"gpt_icon":0},{"id":"2621724300","title":"China Traditional Chinese Medicine Swings to Loss in 2025; Shares Fall 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621724300","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621724300?lang=en_us&edition=fundamental","pubTime":"2026-03-23 13:32","pubTimestamp":1774243925,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine  posted a loss attributable to owners of 342.1 million yuan for 2025, compared with a profit of 54.1 million yuan a year earlier, according to a March 20 Hong Kong bourse filing.Shares of the medicine firm fell nearly 4% in Monday afternoon trade.Loss per share came in at 0.0679 yuan, compared with earnings of 0.0107 yuan a year earlier.Revenue declined year on year to 14.7 billion yuan from 16.5 billion yuan.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","00570","BK1606","BK1515"],"gpt_icon":0},{"id":"2621791718","title":"China Traditional Chinese Medicine (SEHK:570) Half Year Loss Challenges Turnaround Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2621791718","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621791718?lang=en_us&edition=fundamental","pubTime":"2026-03-22 03:09","pubTimestamp":1774120142,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings (SEHK:570) has reported its FY 2025 first half results with revenue of C¥7.5b and a basic EPS loss of C¥0.02, while the trailing twelve months show revenue of C¥14.7b and a basic EPS loss of C¥0.07. Over recent half year periods, revenue has moved from C¥8.4b with EPS of C¥0.04 in 1H 2024 to C¥8.1b with an EPS loss of C¥0.03 in 2H 2024, then to C¥7.5b with an EPS loss of C¥0.02 in 1H 2025, setting up a story where investors are weighing weaker...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-570/china-traditional-chinese-medicine-holdings-shares/news/china-traditional-chinese-medicine-sehk570-half-year-loss-ch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-570/china-traditional-chinese-medicine-holdings-shares/news/china-traditional-chinese-medicine-sehk570-half-year-loss-ch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1515","00570","BK1606","BK1191"],"gpt_icon":0},{"id":"1180584365","title":"TRAD CHI MED (00570) Reports Annual Net Loss of RMB 458 Million, Swinging from Prior Year's Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=1180584365","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180584365?lang=en_us&edition=fundamental","pubTime":"2026-03-20 22:34","pubTimestamp":1774017268,"startTime":"0","endTime":"0","summary":"TRAD CHI MED (00570) announced its annual results for the period ending December 31, 2025. The group's revenue was RMB 147.45 billion, a decrease of 10.7% compared to the previous year. The company...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","00570","BK1606"],"gpt_icon":0},{"id":"1175191192","title":"BAIYUNSHAN PH (00874) Announces Final Dividend of HK$0.45 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1175191192","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175191192?lang=en_us&edition=fundamental","pubTime":"2026-03-20 22:32","pubTimestamp":1774017170,"startTime":"0","endTime":"0","summary":"BAIYUNSHAN PH (00874) has declared a final dividend of HK$0.45 per share for the financial year ending December 31, 2025.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1606","VIG","BK0175","600332","BK0239","BK0096","BK0196","BK1197","BK0028","BK0012","BK0097","BK0183","BK4585","00874","BK0070","BK1521","BK0188","BK1191","BK1515"],"gpt_icon":0},{"id":"1106492723","title":"BAIYUNSHAN PH Reports Annual Results with 5.21% Increase in Net Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=1106492723","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106492723?lang=en_us&edition=fundamental","pubTime":"2026-03-20 22:32","pubTimestamp":1774017143,"startTime":"0","endTime":"0","summary":"BAIYUNSHAN PH (00874) announced its annual results for the period ending December 31, 2025. The group achieved operating revenue of 77.656 billion yuan, representing a year-on-year increase of 3.55%....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","BK1197","00874","BK0175","BK0183","BK0188","BK1515","BK0028","BK0012","BK0096","BK1191","BK0070","BK0097","BK0239","600332","BK0196","BK1606"],"gpt_icon":0},{"id":"2620732365","title":"China Traditional Chinese Medicine Holdings -  Loss for Year RMB458.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2620732365","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620732365?lang=en_us&edition=fundamental","pubTime":"2026-03-20 22:25","pubTimestamp":1774016733,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4080SQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","BK1515","00570","BK1191"],"gpt_icon":0},{"id":"2620732559","title":"China Traditional Chinese Medicine FY2025 revenue fell 10.7% to RMB 14.74 billion, adjusted net profit dropped 47.5% to RMB 333.35 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620732559","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620732559?lang=en_us&edition=fundamental","pubTime":"2026-03-20 22:25","pubTimestamp":1774016722,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine FY2025 revenue fell 10.7% to RMB 14.74 billion, adjusted net profit dropped 47.5% to RMB 333.35 million. China Traditional Chinese Medicine published an annual results announcement for the year ended Dec. 31, 2025.Revenue fell 10.7% to RMB14.74 billion, while gross profit declined 9.7% to RMB7.09 billion.The company reported a net loss of RMB458.09 million and a basic loss per share of 6.79 RMB cents.By segment, revenue from Chinese medicinal herbs integration dropped 40.2% to RMB829.72 million due to exiting high-risk, low-margin business and lower herb selling prices, and concentrated TCM granules revenue fell 12.5% to RMB6.1 billion amid volume-based procurement and tougher competition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fina","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL8QLJrv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00570","BK1606","BK1515"],"gpt_icon":0},{"id":"2620739697","title":"Tong Ren Tang Technologies subsidiary Tong Ren Tang Chinese Medicine posts 2025 profit of HKD 416.86 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620739697","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620739697?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:07","pubTimestamp":1774012021,"startTime":"0","endTime":"0","summary":"Tong Ren Tang Chinese Medicine, a subsidiary of Tong Ren Tang Technologies, reported revenue of HKD 1.51 billion, compared with HKD 1.61 billion.Profit for the year was HKD 416.86 million, versus HKD 529.17 million.Basic and diluted earnings per share were HKD 0.47, compared with HKD 0.6.Total assets were HKD 4.66 billion, compared with HKD 4.56 billion.Cash and cash equivalents were HKD 2.23 billion, versus HKD 1.77 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tong Ren Tang Technologies Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL6bBw6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613","BK0183","BK1191","BK0012","BK0113","BK0196","BK0086","BK0028","BK1583","LU1688375341.USD","600085","BK0239","BK0188","BK0097","BK1515","BK1606","01666"],"gpt_icon":0},{"id":"1163243158","title":"Tongrentang CM to Distribute Final Dividend of HK$0.37 Per Share on June 26","url":"https://stock-news.laohu8.com/highlight/detail?id=1163243158","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163243158?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:06","pubTimestamp":1774011975,"startTime":"0","endTime":"0","summary":"TONGRENTANGCM (03613) announced that it will distribute a final dividend of HK$0.37 per share for the fiscal year ended December 31, 2025, on June 26, 2026.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VIG","BK4585","03613","BK1191","BK1606"],"gpt_icon":0},{"id":"2620236826","title":"Modern Chinese Medicine Group sets board meeting to approve annual results and consider final dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2620236826","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620236826?lang=en_us&edition=fundamental","pubTime":"2026-03-18 16:55","pubTimestamp":1773824138,"startTime":"0","endTime":"0","summary":"Modern Chinese Medicine Group will hold a board meeting on 30 March 2026 to consider and approve its annual results for the year ended 31 December 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modern Chinese Medicine Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6Xzc3v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1191","01643"],"gpt_icon":0},{"id":"1197030422","title":"GPC and Baiyunshan Launch Phase One of Financial Transformation Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=1197030422","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197030422?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:50","pubTimestamp":1773755450,"startTime":"0","endTime":"0","summary":"On March 13, Guangzhou Pharmaceutical Holdings Limited (GPC) and Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited jointly held a kick-off meeting for the first phase of their financial...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00874","BK0028","BK0096","BK0196","BK0183","BK1191","BK0070","BK1197","BK0175","BK0188","BK1521","BK0097","BK1606","600332","BK0239","BK1515","BK0012"],"gpt_icon":0},{"id":"2620841258","title":"Baiyunshan Pharma's Subsidiary Gets Nod for Xu Han Ting Granules' Trial As Respiratory Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2620841258","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620841258?lang=en_us&edition=fundamental","pubTime":"2026-03-17 11:21","pubTimestamp":1773717676,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical's  subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trial of Xu Han Ting Granules for a new indication, according to a Shanghai bourse filing on Tuesday.The drug will be tested as a treatment for recurrent respiratory tract infections in children.The pharmaceutical company's Hong Kong shares rose 2% during the morning trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","00874","BK1191","BK0028","BK0196","BK0175","BK0239","BK1606","BK0070","BK0096","BK0188","BK1521","600332","BK1197","BK0097","BK0183","BK0012"],"gpt_icon":0},{"id":"1192730058","title":"Hong Kong Market Announcements: Ant Group's Acquisition of Bright Smart Receives Approval, Trading Resumes March 17","url":"https://stock-news.laohu8.com/highlight/detail?id=1192730058","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192730058?lang=en_us&edition=fundamental","pubTime":"2026-03-17 09:18","pubTimestamp":1773710304,"startTime":"0","endTime":"0","summary":"Major Corporate Developments: Hengrui Pharma (01276) announced that its SHR-1819 injection and SHR-1905 injection have received drug clinical trial approval notices. Henlius (02696) disclosed that...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"86c6cd7c917d7913316e328a31a00c76","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","BK1191","LU1023057109.AUD","02696","BK1161","02565","01428","LU2543165471.USD","06688","HK0000306685.HKD","BK1147","BK4585","HK0000320264.USD","LU0359201612.USD","LU0359202008.SGD","HK0000306701.USD","BK1515","LU0359201885.HKD","VXUS","HK0000165453.HKD","BK1197","00874","HK0000320223.HKD","BK1606","01276","BK4588"],"gpt_icon":1},{"id":"1120935628","title":"Clinical Trial Application for Baiyunshan's Xuhanting Granules in Pediatric Recurrent Respiratory Infections Receives Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1120935628","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120935628?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:35","pubTimestamp":1773657311,"startTime":"0","endTime":"0","summary":"Baiyunshan (00874) has announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National Medical Products...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0183","BK0239","BK0028","BK0097","BK0188","BK0196","BK1191","00874","BK1197","BK1515","600332","BK0096","BK0012","BK1521","BK1606","BK0070"],"gpt_icon":0},{"id":"1187845305","title":"Baiyunshan Receives SSE Approval for Guangzhou Pharmaceutical Receivables ABS Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1187845305","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187845305?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:31","pubTimestamp":1773657074,"startTime":"0","endTime":"0","summary":"Baiyushan PH (00874) announced that on March 13, 2026, the company received a no-objection letter from the Shanghai Stock Exchange (SSE) forwarded by Industrial Securities Asset Management Co., Ltd....","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0097","BK0028","BK1161","BK0012","BK0096","BK1197","BK1574","BK1515","BK0188","BK0183","09939","600332","BK0196","BK0239","161027","BK0070","BK1191","BK1521","159938","00874","BK1606","BK0175"],"gpt_icon":0},{"id":"2618498017","title":"China Traditional Chinese Medicine Holdings schedules board meeting to approve 2025 final results and dividend decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2618498017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618498017?lang=en_us&edition=fundamental","pubTime":"2026-03-10 16:31","pubTimestamp":1773131482,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings will hold a board meeting on 20 March 2026 to consider and approve the group’s final results for the year ended 31 December 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Traditional Chinese Medicine Holdings Co. Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL2FTTKr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","00570","BK1191","BK1606"],"gpt_icon":0},{"id":"2618861281","title":"Jacobson Pharma, JBM Renew Logistics, Manufacturing Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2618861281","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618861281?lang=en_us&edition=fundamental","pubTime":"2026-03-09 13:50","pubTimestamp":1773035408,"startTime":"0","endTime":"0","summary":"Jacobson Pharma  and JBM   renewed logistics and manufacturing services agreements for three years from April 1, 2026, to March 31, 2029, according to a March 6 joint Hong Kong bourse filing.Under the agreements, the Jacobson group will continue providing logistics services to the JBM group, while the JBM group will provide manufacturing services for certain generic drugs to Jacobson.Annual caps for the logistics services are set at HK$8 million for the year ending March 2027, HK$9 million for 2028, and HK$10 million for 2029.Caps for the manufacturing services are HK$7 million, HK$8 million, and HK$9 million for the respective years, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK1606","02161","02633"],"gpt_icon":0},{"id":"1106239460","title":"JPMorgan Reduces Stake in BAIYUNSHAN PH, Selling 207,200 Shares at HK$18.75 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1106239460","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106239460?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:00","pubTimestamp":1773014448,"startTime":"0","endTime":"0","summary":"Latest data from the Hong Kong Stock Exchange reveals that on March 3, JPMorgan reduced its holdings in BAIYUNSHAN PH (00874) by 207,200 shares. The transaction was executed at a price of HK$18.7486...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JPM","LU0149725797.USD","IE00BLSP4452.SGD","LU0211331839.USD","LU1917777945.USD","LU2264538146.SGD","BK1606","LU0689472784.USD","IE00BDRTCR15.USD","IE00BJLML261.HKD","LU1116320901.HKD","LU0496365809.HKD","BK0175","LU1720051017.SGD","LU0320765646.SGD","LU2237443465.HKD","LU1894683264.USD","LU0106831901.USD","LU1267930490.SGD","IE00BJTD4V19.USD","BK0196","LU0820561909.HKD","LU2746668461.USD","LU0208291251.USD","LU1064131342.USD","LU1496350171.SGD","LU2237443622.USD","IE00BKDWB100.SGD","LU0267386448.USD","LU1116320737.USD","LU2592432038.USD","LU1894683348.USD","IE00BN8TJ469.HKD","IE0034235188.USD","LU2756315318.SGD","LU1496350502.SGD","LU2237443895.HKD","IE00BYXW3230.USD","LU0265550946.USD","LU0787776722.HKD","LU0323591593.USD","IE00BJTD4N35.SGD","IE00BWXC8680.SGD","BK0028","LU1366192091.USD","IE00B775SV38.USD","LU0345770993.USD","BK1515","LU1629891620.HKD","SG9999002232.USD","IE00BHPRN162.USD","BK0183","LU0234572021.USD","LU2237443549.SGD","LU2756315664.SGD","LU2505996509.AUD","LU2552382132.HKD","IE00BBT3K403.USD","LU2023250330.USD","JPMO","LU0683600562.USD","LU0215105999.USD","IE0034235303.USD","LU1244550494.USD","LU2236285917.USD","IE00BZ1G4Q59.USD","LU2552382215.SGD","LU2054465674.USD","LU0964807845.USD","LU1244550221.USD","LU2417539215.USD","LU0211326755.USD","LU2237443978.SGD","LU1145028129.USD","LU0048584097.USD","IE00BFXG1179.USD","LU1162221912.USD","LU1084165304.USD","LU0345770308.USD","LU1670628061.USD","LU1720051108.HKD","IE000M9KFDE8.USD","BK1191","LU2430703178.SGD","LU1668664300.SGD","LU1244550577.SGD","LU0976567544.SGD","LU1119994496.HKD","LU0971096721.USD","BK4566","LU1363072403.SGD","LU1280957306.USD","LU0820561818.USD","LU0417517546.SGD","BK4207","IE00B1BXHZ80.USD","IE00BDCRKT87.USD","600332","LU2381873111.SGD","LU2242649171.HKD","IE0034235295.USD","LU0211326839.USD","LU0345769128.USD","LU1914381329.SGD","BK4504","LU2237443382.USD","BK1521","LU0943347566.SGD","LU1551013425.SGD","BK4585","BK4581","BK0070","BK0239","LU0070302665.USD","LU0211328371.USD","LU0320765489.SGD","LU2357305700.SGD","BK0096","IE00BLSP4239.USD","00874","LU0203347892.USD","BK0012","LU1032466523.USD","LU0238689110.USD","BK4516","LU2505996681.GBP","LU2552382058.USD","LU0868494708.USD","LU0251132253.USD","LU2456880835.USD","BK0188","LU0256863811.USD","BK1197","LU1548497426.USD","LU0868494617.USD","LU2746668974.SGD","LU2211815571.USD","BK4533","LU0106261372.USD","LU1551013342.USD","LU2213496289.HKD","LU2462157665.USD","BK4550","BK0097","LU2023250504.SGD","LU0345769631.USD","BK4534","LU0640476718.USD","LU0310799852.SGD","LU2430703095.HKD","LU2430703251.USD","BK4588","SG9999002224.SGD","IE00B1XK9C88.USD","LU0820562030.AUD","LU0265550359.USD","LU0942090050.USD","LU1670627923.USD","LU1261432733.SGD","LU1974910355.USD","IE00B3S45H60.SGD","LU0211327993.USD","LU1988902786.USD","LU0170899867.USD","LU0006306889.USD","IE00BKVL7J92.USD","LU0203345920.USD","LU0882574139.USD","LU2023250843.SGD","LU2106854487.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}